進行性多巣性白質脳症治療の世界市場レポート 2025年

進行性多巣性白質脳症治療の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR10.2％で23億8,000万米ドルに成長します。予測期間の成長は、デジタルヘルスと遠隔医療の増加、標的治療の採用拡大、診断ツールの改善、進行性多巣性白質脳症（PML）の認知度の高まりに起因すると考えられます。予測期間の主な動向には、進行性多巣性白質脳症（PML）治療の技術進歩、研究開発と臨床試験、早期診断とスクリーニング、新薬治療開発などが含まれます。

進行性多巣性白質脳症（PML）市場拡大の原動力として、ヒト免疫不全ウイルス（HIV）感染率の増加が予想されています。レトロウイルスの一種であるHIVは、免疫系、特にCD4細胞（T細胞としても知られる）を標的とし、感染に対する身体の防御において重要な役割を果たします。PMLは、CD4細胞数の低下（200/L以下）を特徴とする免疫不全のため、HIV感染患者に最も多く見られ、これが世界のPML症例の主な要因となっています。HIVに関連した重度の免疫不全があると、脳内に潜伏しているジョン・カニンガム・ウイルス（JCV）の原型株が活性化し、脳白質病変やPMLの発症につながる可能性があります。例えば、2022年12月現在、スイスを拠点とするエイズに焦点を当てた国連のイニシアチブである国連合同エイズ計画（UNAIDS）のデータによると、63万人（48万～88万人）がエイズ関連疾患で死亡し、世界でHIVとともに生きる人は3,900万人（3,310万～4,570万人）です。2022年には、さらに130万人（100万～170万人）が新たにHIVと診断されました。その結果、HIV感染の有病率の増加が進行性多巣性白質脳症市場の成長を促進する主要因となっています。

進行性多巣性白質脳症（PML）治療市場の成長は、研究開発（R&D）活動の増加によって促進されると予想されます。これらの活動には、様々な分野にわたる科学的探求、実験、技術革新への努力と投資の高まりが含まれます。研究開発は、治療法の改善、早期診断、疾患管理戦略の強化につながるため、PMLの治療と管理を進める上で不可欠です。例えば、2023年12月、ルクセンブルクを拠点とする政府機関ユーロスタットは、EUが2022年に研究開発費として3,520億ユーロ（約3,804億円）を割り当て、2021年の3,310億ユーロ（約3,577億1,000万円）から6.34％増加したと報告しました。このように、研究開発への取り組みの高まりがPML治療市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界進行性多巣性白質脳症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の進行性多巣性白質脳症治療市場：成長率分析
• 世界の進行性多巣性白質脳症治療市場の実績：規模と成長, 2019-2024
• 世界の進行性多巣性白質脳症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界進行性多巣性白質脳症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の進行性多巣性白質脳症治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗レトロウイルス療法
• 抗ウイルス薬または抗ジョン・カニンガムウイルス（JCV）
• その他の症状
• 世界の進行性多巣性白質脳症治療市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• HIVまたはエイズ
• 臓器移植
• 多発性硬化症
• 造血悪性腫瘍
• 世界の進行性多巣性白質脳症治療市場投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の進行性多巣性白質脳症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界の進行性多巣性白質脳症治療市場抗レトロウイルス療法の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• NRTI（ヌクレオシド逆転写酵素阻害剤）
• NNRTI（非ヌクレオシド系逆転写酵素阻害剤）
• PI（プロテアーゼ阻害剤）
• インテグラーゼ阻害剤
• 世界の進行性多巣性白質脳症治療市場、抗ウイルスまたは抗ジョン・カニンガムウイルス（JCV）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナタリズマブ
• フマル酸エステル
• その他のJCV標的療法
• 世界の進行性多巣性白質脳症治療市場、その他の対症療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 免疫調節薬
• 支持療法
• 症状緩和薬

第7章 地域別・国別分析

• 世界の進行性多巣性白質脳症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の進行性多巣性白質脳症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 進行性多巣性白質脳症治療市場：競合情勢
• 進行性多巣性白質脳症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Bristol Myers Squibb Company
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Acorda Therapeutics
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Eisai Co. Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Jazz Pharmaceuticals plc
• Ipsen Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 進行性多巣性白質脳症治療市場2029：新たな機会を提供する国
• 進行性多巣性白質脳症治療市場2029：新たな機会を提供するセグメント
• 進行性多巣性白質脳症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Progressive multifocal leukoencephalopathy is a rare and severe viral brain infection that primarily afflicts individuals with weakened immune systems. Treatment aims to manage symptoms, slow the disease's progression, and prevent complications. Unfortunately, there is currently no known cure for PML, and the damage caused by the virus cannot be reversed.

The main treatment approaches for progressive multifocal leukoencephalopathy include anti-retroviral therapy, antiviral or anti-John Cunningham virus (JCV) medications, and other interventions. Anti-retroviral therapy involves a combination of drugs used to manage infections caused by retroviruses, especially the human immunodeficiency virus (HIV). These therapies are employed in conditions such as HIV/AIDS, organ transplantation, multiple sclerosis, and hematologic malignancies. They can be administered through various methods, including oral and parenteral routes, and are utilized by a range of healthcare facilities, including hospitals, homecare services, specialty centers, and more.

The progressive multifocal leukoencephalopathy market research report is one of a series of new reports from The Business Research Company that provides progressive multifocal leukoencephalopathy market statistics, including progressive multifocal leukoencephalopathy industry global market size, regional shares, competitors with a progressive multifocal leukoencephalopathy market share, detailed progressive multifocal leukoencephalopathy market segments, market trends and opportunities and any further data you may need to thrive in the progressive multifocal leukoencephalopathy industry. This progressive multifocal leukoencephalopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.46 billion in 2024 to $1.61 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of HIV/aids epidemic.

The progressive multifocal leukoencephalopathy treatment market size is expected to see rapid growth in the next few years. It will grow to $2.38 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing digital health and telemedicine, growing adoption of targeted therapy, improved diagnostic tools, growing awareness of progressive multifocal leukoencephalopathy (PML). Major trends in the forecast period include technological advancements in progressive multifocal leukoencephalopathy (PML) treatment, research and clinical trials, early diagnosis and screening, development of new drug therapies.

The expected increase in the prevalence of human immunodeficiency virus (HIV) infection is anticipated to be a driving force behind the expansion of the progressive multifocal leukoencephalopathy (PML) market. HIV, a retrovirus, targets the immune system, specifically CD4 cells (also known as T cells), which play a crucial role in the body's defense against infections. PML is most commonly observed in patients with HIV due to their compromised immune status, often characterized by a low CD4 cell count (below 200/L), which is the primary factor contributing to PML cases worldwide. When there is a severe immune deficiency related to HIV, the latent John Cunningham virus (JCV) archetype strain in the brain can become active, leading to the development of brain white matter lesions and PML. For instance, as of December 2022, data from the Joint United Nations Programme on HIV and AIDS (UNAIDS), a Switzerland-based United Nations initiative focused on AIDS, indicates that 630,000 (480,000-880,000) people succumbed to AIDS-related illnesses, and there were 39.0 million (33.1 million-45.7 million) individuals living with HIV worldwide. In 2022, an additional 1.3 million (1 million-1.7 million) people were newly diagnosed with HIV. Consequently, the increasing prevalence of HIV infection is a key factor propelling the growth of the progressive multifocal leukoencephalopathy market.

The growth of the progressive multifocal leukoencephalopathy (PML) treatment market is anticipated to be fueled by increasing research and development (R&D) activities. These activities encompass heightened efforts and investments in scientific exploration, experimentation, and innovation across various sectors. R&D is essential for advancing the treatment and management of PML, as it leads to the creation of improved therapies, earlier diagnoses, and enhanced disease management strategies. For example, in December 2023, Eurostat, a Luxembourg-based government agency, reported that the European Union allocated €352 billion ($380.40 billion) to R&D in 2022, marking a 6.34% increase from the €331 billion ($357.71 billion) invested in 2021. Thus, the rise in research and development efforts is driving growth in the PML treatment market.

Leading companies in the progressive multifocal leukoencephalopathy (PML) treatment market are increasingly dedicating their efforts to innovating their products to offer reliable solutions to their customers and to bolster their market standing. As an example, in October 2022, Cellevolve Bio, a clinical company based in the United States, obtained clearance from the United States Food and Drug Administration (FDA) for an investigational new drug (IND) application and secured orphan drug designation for CE-VST01-JC. This drug is developed to address progressive multifocal leukoencephalopathy and will undergo assessment in a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 trial named ASCEND-JC. The primary objective of this trial is to compare the efficacy of CE-VST01-JC with a placebo, aiming to determine whether CE-VST01-JC can mitigate or prevent neurological progression in patients with PML. CE-VST01-JC is a T-cell therapy precisely targeting the JC virus, the causal agent of PML. This represents a significant milestone for both the PML community and Cellevolve, as ASCEND-JC stands as the largest-ever cell treatment study in the realm of PML research.

In March 2022, Cellevolve Bio, a US-based company focused on the treatment of progressive multifocal leukoencephalopathy, formed a partnership with Seattle Children's Therapeutics. This collaboration aims to enhance the BrainChild research program, which is dedicated to developing multiplex chimeric antigen receptors (CARs) for the treatment of pediatric central nervous system (CNS) malignancies. Seattle Children's Therapeutics is a non-profit enterprise in the United States that specializes in therapeutics development.

Major companies operating in the progressive multifocal leukoencephalopathy treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Acorda Therapeutics, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Ipsen Pharma, Apotex Inc., Alkermes PLC, Alnylam Pharmaceuticals Inc., Genentech Inc., Karyopharm Therapeutics Inc., ARIAD Pharmaceuticals Inc., Spectrum Pharmaceuticals, Neurimmune AG, NeoImmuneTech, Inhibikase Therapeutics Inc.

North America was the largest region in the progressive multifocal leukoencephalopathy treatment market in 2024. The regions covered in the progressive multifocal leukoencephalopathy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the progressive multifocal leukoencephalopathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The progressive multifocal leukoencephalopathy treatment market consists of revenues earned by entities by providing plasmapheresis, immune reconstitution therapy, physical therapy, supportive care, and consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The progressive multifocal leukoencephalopathy treatment market also includes sales of cidofovir, Brin cidofovir, and mefloquine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on progressive multifocal leukoencephalopathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for progressive multifocal leukoencephalopathy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The progressive multifocal leukoencephalopathy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Anti-retroviral Therapy; Antiviral Or Anti-John Cunningham Virus (JCV); Other Symptomatic
• 2) By Indication: HIV Or AIDS; Organ Transplantation; Multiple Sclerosis; Hematologic Malignancies
• 3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
• Subsegments:
• 1) By Anti-retroviral Therapy: NRTIs (Nucleoside Reverse Transcriptase Inhibitors); NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors); PIs (Protease Inhibitors); Integrase Inhibitors
• 2) By Antiviral Or Anti-John Cunningham Virus (JCV): Natalizumab; Fumaric Acid Esters; Other JCV-targeted Therapies
• 3) By Other Symptomatic Treatments: Corticosteroids; Immunomodulators; Supportive Care; Symptomatic Relief Medications
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Progressive Multifocal Leukoencephalopathy Treatment Market Characteristics

3. Progressive Multifocal Leukoencephalopathy Treatment Market Trends And Strategies

4. Progressive Multifocal Leukoencephalopathy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Progressive Multifocal Leukoencephalopathy Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Progressive Multifocal Leukoencephalopathy Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Progressive Multifocal Leukoencephalopathy Treatment Market Growth Rate Analysis
• 5.4. Global Progressive Multifocal Leukoencephalopathy Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Progressive Multifocal Leukoencephalopathy Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Progressive Multifocal Leukoencephalopathy Treatment Total Addressable Market (TAM)

6. Progressive Multifocal Leukoencephalopathy Treatment Market Segmentation

• 6.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-retroviral Therapy
• Antiviral Or Anti-John Cunningham Virus (JCV)
• Other Symptomatic
• 6.2. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HIV Or AIDS
• Organ Transplantation
• Multiple Sclerosis
• Hematologic Malignancies
• 6.3. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centers
• Other End-Users
• 6.5. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Sub-Segmentation Of Anti-retroviral Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• NRTIs (Nucleoside Reverse Transcriptase Inhibitors)
• NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)
• PIs (Protease Inhibitors)
• Integrase Inhibitors
• 6.6. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Sub-Segmentation Of Antiviral Or Anti-John Cunningham Virus (JCV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natalizumab
• Fumaric Acid Esters
• Other JCV-targeted Therapies
• 6.7. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Sub-Segmentation Of Other Symptomatic Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunomodulators
• Supportive Care
• Symptomatic Relief Medications

7. Progressive Multifocal Leukoencephalopathy Treatment Market Regional And Country Analysis

• 7.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market

• 8.1. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Progressive Multifocal Leukoencephalopathy Treatment Market

• 9.1. China Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 9.2. China Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Progressive Multifocal Leukoencephalopathy Treatment Market

• 10.1. India Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Progressive Multifocal Leukoencephalopathy Treatment Market

• 11.1. Japan Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 11.2. Japan Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Progressive Multifocal Leukoencephalopathy Treatment Market

• 12.1. Australia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Progressive Multifocal Leukoencephalopathy Treatment Market

• 13.1. Indonesia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market

• 14.1. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 14.2. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market

• 15.1. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 15.2. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Progressive Multifocal Leukoencephalopathy Treatment Market

• 16.1. UK Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Progressive Multifocal Leukoencephalopathy Treatment Market

• 17.1. Germany Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Progressive Multifocal Leukoencephalopathy Treatment Market

• 18.1. France Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Progressive Multifocal Leukoencephalopathy Treatment Market

• 19.1. Italy Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Progressive Multifocal Leukoencephalopathy Treatment Market

• 20.1. Spain Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market

• 21.1. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 21.2. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Progressive Multifocal Leukoencephalopathy Treatment Market

• 22.1. Russia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Progressive Multifocal Leukoencephalopathy Treatment Market

• 23.1. North America Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 23.2. North America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Progressive Multifocal Leukoencephalopathy Treatment Market

• 24.1. USA Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 24.2. USA Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Progressive Multifocal Leukoencephalopathy Treatment Market

• 25.1. Canada Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 25.2. Canada Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Progressive Multifocal Leukoencephalopathy Treatment Market

• 26.1. South America Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 26.2. South America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market

• 27.1. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market

• 28.1. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 28.2. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Progressive Multifocal Leukoencephalopathy Treatment Market

• 29.1. Africa Progressive Multifocal Leukoencephalopathy Treatment Market Overview
• 29.2. Africa Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administratio, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Progressive Multifocal Leukoencephalopathy Treatment Market Competitive Landscape And Company Profiles

• 30.1. Progressive Multifocal Leukoencephalopathy Treatment Market Competitive Landscape
• 30.2. Progressive Multifocal Leukoencephalopathy Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Progressive Multifocal Leukoencephalopathy Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Bristol Myers Squibb Company
• 31.3. Sanofi S.A.
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Acorda Therapeutics
• 31.6. Eli Lilly and Company
• 31.7. Gilead Sciences Inc.
• 31.8. Amgen Inc.
• 31.9. Viatris Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Biogen Inc.
• 31.12. Eisai Co. Ltd.
• 31.13. Otsuka Pharmaceutical Co. Ltd.
• 31.14. Jazz Pharmaceuticals plc
• 31.15. Ipsen Pharma

32. Global Progressive Multifocal Leukoencephalopathy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Progressive Multifocal Leukoencephalopathy Treatment Market

34. Recent Developments In The Progressive Multifocal Leukoencephalopathy Treatment Market

35. Progressive Multifocal Leukoencephalopathy Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Progressive Multifocal Leukoencephalopathy Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Progressive Multifocal Leukoencephalopathy Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Progressive Multifocal Leukoencephalopathy Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer